Enhabit Reports Second Quarter 2024 Financial Results

Enhabit Reports Second Quarter 2024 Financial Results

August 06, 2024 | Last Trade: US$7.46 0.19 2.61

NYSE: EHAB

Healthcare

Healthcare Services

Financial Results

VISIT WEBSITE

Company to host a conference call tomorrow, August 7, 2024, at 10 a.m. EDT

DALLAS / Aug 06, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2024.

“The second quarter marked our third sequential quarter demonstrating the success of our strategies,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “In our home health segment, our total admissions growth of 6.4% was driven by our payor innovation strategy and our focus on improved utilization of our clinical resources. In our hospice segment, we continued to make steady progress in growing our census, with average daily census increasing each month since January 2024. Our focus on recruitment and retention continues to position us for long-term growth, and we remain confident in the long-range growth potential for Enhabit.”

QUARTERLY PERFORMANCE - CONSOLIDATED

Net service revenue of $260.6 million
Net loss attributable to Enhabit, Inc. of $0.2 million
Adjusted EBITDA of $25.2 million
Earnings per share of $0.00
Adjusted earnings per share of $0.07

RECENT COMPANY HIGHLIGHTS

Non-Medicare admissions grew 25.2%, driving total admission growth of 6.4% year over year
- 43% of non-Medicare visits are now in payor innovation contracts at improved rates
30-day hospitalization readmission rate in home health is 23.3% better than the national average
Hospice average daily census increased 2.7% year over year
- Average daily census increased sequentially every month since January
53.2% better than the national average for hospice patient visits in last days of life
Reduced bank debt by $15 million in the quarter
Opened one home health de novo location in Florida in April

FINANCIAL RESULTS
Consolidated

*($ in millions, except per share data)*	Q2						'24 vs. '23
	2024			2023			'24 vs. '23
Home health net service revenue	$		210.2	$		213.8	(1.7) %
Hospice net service revenue			50.4			48.5	3.9 %
Total net service revenue	$		260.6	$		262.3	*(0.6) %*
	% of revenue			% of revenue
Cost of service	50.6 %	$	131.8	51.7 %	$	135.5	(2.7) %
Gross margin	49.4 %		128.8	48.3 %		126.8	1.6 %
General and administrative expenses	39.5 %		103.0	39.2 %		102.7	0.3 %
Total operating expenses	90.1 %	$	234.8	90.8 %	$	238.2	(1.4) %
Other income			—			(0.1)
Net income attributable to noncontrolling interests			0.6			0.3
Adjusted EBITDA	$		25.2	$		23.9	*5.4 %*
*Adjusted EBITDA margin*			*9.7 %*			*9.1 %*
Impairment of goodwill	$		—	$		85.8	*(100.0) %*
Net loss attributable to Enhabit, Inc.	$		(0.2)	$		(74.4)	*(99.7) %*
Reported diluted EPS	$		—	$		(1.49)	*(100.0) %*
Adjusted EPS	$		0.07	$		0.04	*75.0 %*

Consolidated Adjusted EBITDA grew 5.4% year over year through cost management in home health and revenue growth in hospice.

SEGMENT RESULTS
Home Health

*($ in millions)*	Q2				'24 vs. '23
	2024		2023		'24 vs. '23
Net service revenue:
Medicare	$	121.7	$	139.4	(12.7)%
Non-Medicare		86.3		71.8	20.2%
Private duty⁽¹⁾		2.2		2.6	(15.4)%
Home health net service revenue		210.2		213.8	(1.7)%
Cost of service		106.9		111.4	(4.0)%
Gross margin		49.1%		47.9%
General and administrative expenses		58.6		59.4	(1.3)%
Other income		—		(0.1)	(100.0)%
Net income attributable to noncontrolling interests		0.5		0.3	66.7%
Adjusted EBITDA	$	44.2	$	42.8	3.3%
% Adj. EBITDA margin		21.0%		20.0%
Operational metrics (actual amounts)
Medicare:
Admissions		24,015		26,845	(10.5)%
Recertifications		16,639		19,884	(16.3)%
Completed episodes		41,620		47,528	(12.4)%
Visits		597,742		691,857	(13.6)%
Visits per episode		14.4		14.6	(1.4)%
Revenue per episode	$	2,924	$	2,933	(0.3)%
Non-Medicare:
Admissions		30,209		24,130	25.2%
Recertifications		14,587		13,458	8.4%
Visits		581,326		514,008	13.1%
Total:
Admissions		54,224		50,975	6.4%
Same-store total admissions growth					6.2%
Recertifications		31,226		33,342	(6.3)%
Same-store total recertifications growth					(6.5)%
Visits		1,179,068		1,205,865	(2.2)%
Visits per episode		14.0		14.6	(4.1)%
Cost per visit	$	89	$	91	(2.2)%
⁽¹⁾ Private duty represents long-term comprehensive hourly nursing medical care.

Non-Medicare admissions grew 25.2%, driving total admissions growth of 6.4% year over year. Revenue declined $3.6 million, or 1.7%, year over year primarily due to lower Medicare volume as a result of lower recertifications. The net impact of the payor mix shift year over year was a positive $1 million.

Adjusted EBITDA increased $1.4 million, or 3.3% year over year primarily due to lower cost per visit. Cost per visit decreased 2.2% year over year primarily due to a reduction in contract labor and favorable experience in workers’ compensation and group medical claims.

Hospice

*($ in millions)*	Q2				'24 vs. '23
	2024		2023		'24 vs. '23
Net service revenue	$	50.4	$	48.5	3.9 %
Cost of service		24.9		24.1	3.3 %
Gross margin		50.6 %		50.3 %
General and administrative expenses		16.3		16.1	1.2 %
Net income attributable to noncontrolling interests		0.1		—	NM
Adjusted EBITDA	$	9.1	$	8.3	9.6 %
% Adj. EBITDA margin		18.1 %		17.1 %
Operational metrics (actual amounts)
Total admissions		2,888		2,837	1.8 %
Same-store total admissions growth					(0.2) %
Patient days		320,026		311,465	2.7 %
Discharged average length of stay		108		108	— %
Average daily census		3,517		3,423	2.7 %
Revenue per patient day	$	157	$	156	0.6 %
Cost per patient day	$	78	$	77	1.3 %
References in the financial tables to percentage changes that are not meaningful are denoted by “NM”.

Net service revenue increased $1.9 million, or 3.9%, year over year due to increased Medicare reimbursement rates and an increase in patient days. Average daily census increased 3.7% sequentially and has increased sequentially every month since January 2024. Adjusted EBITDA increased $0.8 million, or 9.6%, year over year primarily due to increased revenue. Cost per day increased 1.3% year over year primarily due to increased costs associated with patient supplies, including durable medical equipment and pharmacy.

GUIDANCE

The Company updated its full-year 2024 guidance as follows:

*($ in millions, except per share data)*	2024 Previous Guidance	2024 Updated Guidance
Net service revenue	$1,076 to $1,102	$1,050 to $1,063
Adjusted EBITDA	$98 to $110	$100 to $106
Adjusted EPS	$0.12 to $0.43	$0.19 to $0.37

For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 a.m. EDT on August 7, 2024 to discuss its results for the second quarter of 2024. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/154318091. Following the call, a replay will be available on the Company’s website at http://investors.ehab.com.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 256 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation and reconciliation of non-GAAP financial measures

The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Supplemental Non-GAAP Information” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three and six months ended June 30, 2024, provides further information regarding “unusual or nonrecurring items that are not typical of ongoing operations,” a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024		2023
	($ in millions, except per share data)
Net service revenue	$	260.6		$	262.3		$	523.0	$	527.4
Cost of service, excluding depreciation and amortization		131.8			135.5			266.0		268.1
General and administrative expenses		110.0			107.8			217.5		218.3
Depreciation and amortization		7.6			7.7			15.4		15.5
Impairment of goodwill		—			85.8			—		85.8
Operating income (loss)		11.2			(74.5	)		24.1		(60.3	)
Interest expense and amortization of debt discounts and fees		10.9			10.3			22.0		19.8
Other income		—			(0.1	)		—		(0.1	)
Income (loss) before income taxes and noncontrolling interests		0.3			(84.7	)		2.1		(80.0	)
Income tax (benefit) expense		(0.1	)		(10.6	)		0.8		(9.1	)
Net income (loss)		0.4			(74.1	)		1.3		(70.9	)
Less: Net income attributable to noncontrolling interests		0.6			0.3			1.3		0.8
Net loss attributable to Enhabit, Inc.	$	(0.2	)	$	(74.4	)	$	—	$	(71.7	)

Weighted average common shares outstanding:
Basic		50.1			49.8			50.1		49.8
Diluted		50.1			49.8			50.1		49.8

Loss per common share:
Basic loss per share attributable to Enhabit, Inc. common stockholders	$	—		$	(1.49	)	$	—	$	(1.44	)
Diluted loss per share attributable to Enhabit, Inc. common stockholders	$	—		$	(1.49	)	$	—	$	(1.44	)

Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited)

	June 30, 2024		December 31, 2023
	($ in millions)
Assets
Current assets:
Cash and cash equivalents	$	28.5	$	27.4
Restricted cash		1.7		2.4
Accounts receivable, net of allowances		166.0		164.7
Prepaid expenses and other current assets		10.6		15.6
Total current assets		206.8		210.1
Property and equipment, net		21.6		19.0
Operating lease right-of-use assets		55.0		57.5
Goodwill		1,061.7		1,061.7
Intangible assets, net		69.0		80.0
Other long-term assets		4.9		5.3
Total assets	$	1,419.0	$	1,433.6
Liabilities and stockholders’ equity
Current liabilities:
Current portion of long-term debt	$	23.0	$	22.5
Current operating lease liabilities		11.0		11.8
Accounts payable		8.5		7.6
Accrued payroll		37.0		38.5
Refunds due patients and other third-party payors		10.4		8.2
Accrued medical insurance		9.8		8.4
Other current liabilities		40.4		40.7
Total current liabilities		140.1		137.7
Long-term debt, net of current portion		512.7		530.1
Long-term operating lease liabilities, net of current portion		44.3		45.7
Deferred income tax liabilities		16.4		17.1
Other long-term liabilities		0.1		1.3
Total liabilities		713.6		731.9
Redeemable noncontrolling interests		5.0		5.0
Stockholders’ equity:
Total Enhabit, Inc. stockholders’ equity		674.3		669.7
Noncontrolling interests		26.1		27.0
Total stockholders’ equity		700.4		696.7
Total liabilities and stockholders’ equity	$	1,419.0	$	1,433.6

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited)

	Six Months Ended June 30,
	2024			2023
	($ in millions)
Cash flows from operating activities:
Net income (loss)	$	1.3		$	(70.9	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities—
Depreciation and amortization		15.4			15.5
Amortization of debt related costs		0.7			0.5
Impairment of goodwill		—			85.8
Stock-based compensation		4.0			4.1
Deferred tax benefit		(1.1	)		(11.0	)
Other		(0.1	)		0.9
Changes in assets and liabilities, net of acquisitions—
Accounts receivable, net of allowances		(1.3	)		1.9
Prepaid expenses and other assets		5.9			19.2
Accounts payable		0.1			1.5
Accrued payroll		(1.5	)		(2.6	)
Other liabilities		3.5			(5.7	)
Net cash provided by operating activities		26.9			39.2
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired		—			(2.8	)
Purchases of property and equipment, including capitalized software costs		(2.5	)		(1.7	)
Other		0.8			0.5
Net cash used in investing activities		(1.7	)		(4.0	)
Cash flows from financing activities:
Principal payments on term loan facility		(10.0	)		(10.0	)
Principal payments on revolving credit facility		(10.0	)		(10.0	)
Distributions paid to noncontrolling interests of consolidated affiliates		(2.2	)		(2.5	)
Other		(2.6	)		(3.4	)
Net cash used in financing activities		(24.8	)		(25.9	)
Increase in cash, cash equivalents, and restricted cash		0.4			9.3
Cash, cash equivalents, and restricted cash at beginning of period		29.8			27.2
Cash, cash equivalents, and restricted cash at end of period	$	30.2		$	36.5

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share

	Three Months Ended June 30,					Six Months Ended June 30,
	2024		2023			2024		2023
Diluted earnings per share, as reported	$	—	$	(1.49	)	$	—	$	(1.44	)
Adjustments, net of tax:
Impairment of goodwill		—		1.50			—		1.50
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		0.07		0.03			0.13		0.07
Income tax adjustments⁽²⁾		—		—			0.01		0.01
Adjusted earnings per share	$	0.07	$	0.04		$	0.14	$	0.14

(1)	Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.
(2)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Three Months Ended June 30,
	2024
				Adjustments
	As Reported			Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations			As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	25.2		$	—		$	25.2
Interest expense and amortization of debt discounts and fees		(10.9	)		—			(10.9	)
Depreciation and amortization		(7.6	)		—			(7.6	)
Stock-based compensation		(2.2	)		—			(2.2	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(4.8	)		4.8			—
(Loss) income before income taxes		(0.3	)		4.8			4.5
Income tax benefit (expense)		0.1			(1.3	)		(1.2	)
Net (loss) income attributable to Enhabit, Inc.	$	(0.2	)	$	3.5		$	3.3
Diluted EPS	$	—		$	0.07		$	0.07
Diluted shares		50.1						50.1

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in Q2 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Three Months Ended June 30,
	2023
				Adjustments
	As Reported				Impairment of Goodwill			Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	23.9			$	—		$	—		$	—	$	23.9
Interest expense and amortization of debt discounts and fees		(10.3	)			—			—			—		(10.3	)
Depreciation and amortization		(7.7	)			—			—			—		(7.7	)
Gain on disposal of assets		0.1				—			—			—		0.1
Impairment of goodwill		(85.8	)			85.8			—			—		—
Stock-based compensation		(2.6	)			—			—			—		(2.6	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(2.6	)			—			2.6			—		—
(Loss) income before income taxes		(85.0	)			85.8			2.6			—		3.4
Income tax benefit (expense)		10.6				(11.1	)		(1.0	)		0.1		(1.4	)
Net (loss) income attributable to Enhabit, Inc.	$	(74.4	)		$	74.7		$	1.6		$	0.1	$	2.0
Diluted EPS	$	(1.49	)		$	1.50		$	0.03		$	—	$	0.04
Diluted shares		49.8												49.8

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in Q2 2023 include costs associated with nonroutine litigation and shareholder activism.
(3)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Six Months Ended June 30,
	2024
				Adjustments
	As Reported			Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	50.5		$	—		$	—	$	50.5
Interest expense and amortization of debt discounts and fees		(22.0	)		—			—		(22.0	)
Depreciation and amortization		(15.4	)		—			—		(15.4	)
Gain on disposal of assets		0.2			—			—		0.2
Stock-based compensation		(4.0	)		—			—		(4.0	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(8.5	)		8.5			—		—
Income before income taxes		0.8			8.5			—		9.3
Income tax expense		(0.8	)		(2.2	)		0.6		(2.4	)
Net income attributable to Enhabit, Inc.	$	—		$	6.3		$	0.6	$	6.9
Diluted EPS	$	—		$	0.13		$	0.01	$	0.14
Diluted shares		50.1								50.1

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.
(3)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Six Months Ended June 30,
	2023
				Adjustments
	As Reported				Impairment of Goodwill			Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	49.2			$	—		$	—		$	—	$	49.2
Interest expense and amortization of debt discounts and fees		(19.8	)			—			—			—		(19.8	)
Depreciation and amortization		(15.5	)			—			—			—		(15.5	)
Gain on disposal of assets		0.1				—			—			—		0.1
Impairment of goodwill		(85.8	)			85.8			—			—		—
Stock-based compensation		(4.1	)			—			—			—		(4.1	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(4.9	)			—			4.9			—		—
(Loss) income before income taxes		(80.8	)			85.8			4.9			—		9.9
Income tax benefit (expense)		9.1				(11.1	)		(1.6	)		0.5		(3.1	)
Net (loss) income attributable to Enhabit, Inc.	$	(71.7	)		$	74.7		$	3.3		$	0.5	$	6.8
Diluted EPS	$	(1.44	)		$	1.50		$	0.07		$	0.01	$	0.14
Diluted shares		49.8												49.8

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism.
(3)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Net Income (Loss) to Adjusted EBITDA

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
	($ in millions)
Net income (loss)	$	0.4		$	(74.1	)	$	1.3		$	(70.9	)
Interest expense and amortization of debt discounts and fees		10.9			10.3			22.0			19.8
Income tax (benefit) expense		(0.1	)		(10.6	)		0.8			(9.1	)
Depreciation and amortization		7.6			7.7			15.4			15.5
Gain on disposal of assets		—			(0.1	)		(0.2	)		(0.1	)
Impairment of goodwill		—			85.8			—			85.8
Stock-based compensation		2.2			2.6			4.0			4.1
Net income attributable to noncontrolling interests		(0.6	)		(0.3	)		(1.3	)		(0.8	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		4.8			2.6			8.5			4.9
Adjusted EBITDA	$	25.2		$	23.9		$	50.5		$	49.2

(1)	Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
	($ in millions)
Net cash provided by operating activities	$	9.6		$	9.6		$	26.9		$	39.2
Interest expense, excluding amortization of debt discounts and fees		10.6			10.1			21.3			19.3
Current portion of income tax expense		0.5			0.7			1.9			1.9
Change in assets and liabilities, excluding derivative instrument		0.3			1.2			(6.9	)		(15.0	)
Net income attributable to noncontrolling interests		(0.6	)		(0.3	)		(1.3	)		(0.8	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		4.8			2.6			8.5			4.9
Other		—			—			0.1			(0.3	)
Adjusted EBITDA	$	25.2		$	23.9		$	50.5		$	49.2

(1)	Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Enhabit, Inc. and Subsidiaries Supplemental Non-GAAP Information (Unaudited)

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
	($ in millions)
Net cash provided by operating activities	$	9.6		$	9.6		$	26.9		$	39.2
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		4.8			2.6			8.5			4.9
Capital expenditures for maintenance		(0.7	)		(1.1	)		(2.5	)		(1.7	)
Other working capital adjustments		(1.1	)		(0.5	)		(1.7	)		(1.0	)
Distributions paid to noncontrolling interests of consolidated affiliates		(2.2	)		—			(2.2	)		(2.5	)
Adjusted free cash flow	$	10.4		$	10.6		$	29.0		$	38.9

(1)	Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Reconciliation of Gross Margin to Adjusted EBITDA Margin

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023

Gross margin as a percentage of revenue	49.4 %	48.3 %	49.1 %	49.2 %
General and administrative expenses	(42.2) %	(41.1) %	(41.6) %	(41.4) %
Stock-based compensation	0.9 %	1.0 %	0.8 %	0.8 %
Noncontrolling interests	(0.2) %	(0.1) %	(0.2) %	(0.2) %
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾	1.8 %	1.0 %	1.6 %	0.9 %
Adjusted EBITDA margin	9.7 %	9.1 %	9.7 %	9.3 %

(1)	Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

FORWARD-LOOKING STATEMENTS

Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and health care professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com.

Stock Quote

Last Trade:	US$7.46
Daily Change:	0.19 2.61
Daily Volume:	320,851
Market Cap:	US$375.090M

November 06, 2024 Enhabit Reports Third Quarter 2024 Financial Results July 15, 2024 Enhabit Releases Certain Preliminary Second Quarter 2024 Results July 01, 2024 Enhabit Releases Investor Presentation Demonstrating Execution of Clear Growth Strategy and Path to Unlock Shareholder Value May 08, 2024 Enhabit Reports First Quarter 2024 Financial Results March 06, 2024 Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance LOAD MORE NEWS

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE